Key result
Selective thrombophilia screening and individualized risk-benefit analysis may improve management of hereditary hypercoagulable disorders.
Why the study?
The clinical management of hereditary hypercoagulable disorders has evolved due to complex interactions of acquired and hereditary factors influencing thrombosis risk and the need to balance thrombosis risk against long-term anticoagulation risks.
Management of hereditary hypercoagulable disorders requires an individualized risk-benefit analysis rather than universal lifelong anticoagulation.
The clinical management of individuals with hereditary hypercoaguable disorders has evolved from initial broad recommendations of lifelong anticoagulation after first event of venous thromboembolism to a more intricate individualized risk-benefit analysis as studies have begun to delineate the complexity of interactions of acquired and hereditary factors which determine the predilection to thrombosis. The contribution of thrombophilic disorders to risk of thrombotic complications of pregnancy, organ transplantation, central venous catheter and dialysis access placement have been increasingly recognized. The risk of thrombosis must be weighed against risk of long-term anticoagulation in patients with venous thromboembolism. Thrombophilia screening in select populations may enhance outcome.
No takes yet. Share an insight, caveat, or question.
Paula Bockenstedt (2006) conducted a review in Hereditary hypercoagulable disorders. Individualized risk-benefit analysis and thrombophilia screening was evaluated. Individualized risk-benefit analysis and thrombophilia screening in select populations may enhance outcomes in the management of hereditary hypercoagulable disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: